After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for United Therapeutics Corporation (UTHR) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.89, or -0.36%, to $244.00. The United Therapeutics Corporation has recorded 68,452 volume in the after hours trading session.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
UTHR belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $244.89 and fluctuated between $248.70 as its day high and $241.26 as its day low. The current market capitalization of United Therapeutics Corporation is $11.10B. A total of 0.58 million shares were traded on the day, compared to an average of 442.87K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, UTHR has seen 51 BUY and 266 SELL insider trades, representing the acquisition of 383,700 and the disposition of 460,626 shares. Over the last 12 months, there were 150 BUYs and 590 SELLs from insiders. Insiders purchased 841,361 shares during that period but sold 918,307.
In the most recent transaction, ROTHBLATT MARTINE A sold 8,000 shares of UTHR for 249.14 per share on Feb 27. After the transaction, the CHAIRPERSON & CEO now owns 130 company shares. In a previous transaction on Feb 24, ROTHBLATT MARTINE A sold 8,000 shares at 249.27 per share. UTHR shares that CHAIRPERSON & CEO owns now total 130.
Among the insiders who sold shares, ROTHBLATT MARTINE A disposed of 8,000 shares on Feb 23 at a per-share price of $248.52. This resulted in the CHAIRPERSON & CEO holding 130 shares of UTHR after the transaction. In another insider transaction, ROTHBLATT MARTINE A sold 8,000 shares at $246.77 per share on Feb 22. Company shares held by the CHAIRPERSON & CEO now total 130.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for UTHR in the last 3 months, the mean price target is $287.58 with high estimates of $375.00 and low estimates of $150.00. In terms of 52-week highs and lows, UTHR has a high of $283.09 and a low of $158.38.
As of this writing, UTHR has an earnings estimate of $4.51 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of $5.23 per share and a lower estimate of $3.34. The company reported an EPS of $2.41 in the last quarter, which was -41.60% lower than expectations of $4.13.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 14 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for UTHR is Hold with a score of 4.42. A total of 11 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.